Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Enoxaparin vs LOVENOX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.
Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or medical patients at risk,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) in combination with aspirin,Prophylaxis of ischemic complications in patients with acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
Treatment of deep vein thrombosis (DVT),Prevention of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with restricted mobility,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) when administered with aspirin,Extended treatment of DVT in cancer patients (off-label)
1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.
Terminal elimination half-life is 4.5 hours after a single subcutaneous dose, and 7 hours after repeated dosing, reflecting accumulation. Mean half-life is approximately 4-5 hours in healthy volunteers.
Terminal half-life: 4.5-7 hours after subcutaneous administration; prolonged in renal impairment (up to 16 hours with Cr Cl <30 m L/min), requiring dose adjustment.
Enoxaparin is primarily metabolized in the liver by desulfation and depolymerization; elimination is via renal excretion of low molecular weight fragments.
Primarily metabolized in the liver by desulfation and depolymerization to lower molecular weight fragments with reduced anticoagulant activity.
Renal elimination accounts for 40% of the administered dose, with the remainder undergoing hepatic metabolism and/or distribution. Biliary/fecal excretion is minimal (<5%).
Renal: 40-60% as active and inactive fragments via glomerular filtration and tubular secretion; biliary/fecal: minimal, <10%.
Enoxaparin is highly protein bound (>80%) to antithrombin III and other plasma proteins.
Antithrombin III (ATIII) binding: ~100% (enoxaparin is an ATIII-dependent inhibitor); nonspecific protein binding: negligible (<1%).
Volume of distribution is approximately 0.15-0.25 L/kg (4-6 L total), indicating limited extravascular distribution, primarily confined to the vascular compartment.
Vd: 0.1-0.2 L/kg; confined mainly to intravascular space, with limited extravascular distribution; reflects low tissue penetration.
Subcutaneous: Approximately 92-100% bioavailability based on anti-Xa activity. Oral: negligible due to poor absorption.
Subcutaneous: 92-100% (nearly complete).
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis, reduce to 30 mg subcutaneously once daily.
For Cr Cl <30 m L/min: treatment dose 1 mg/kg subcutaneously once daily; prophylaxis dose 30 mg subcutaneously once daily. No adjustment for Cr Cl 30-50 m L/min but monitor closely.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
No specific dosing adjustment recommended for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment due to increased risk of bleeding.
For treatment of venous thromboembolism: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Dose adjustments based on anti-Xa monitoring.
Prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Treatment: 1 mg/kg subcutaneously every 12 hours. Maximum single dose 120 mg. Weight must be >5 kg.
Increased risk of bleeding; consider lower initial doses and monitor renal function and bleeding closely. No specific dose adjustment solely based on age.
Elderly patients >75 years old: increased risk of bleeding; consider lower doses (e.g., 0.75 mg/kg every 12 hours for treatment) and monitor renal function closely; no specific dose adjustment solely by age but use with caution.
Spinal or epidural hematomas, including subsequent paralysis, may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture. Risk is increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis, history of traumatic or repeated epidural or spinal puncture, or spinal deformity.
Spinal/epidural hematomas may occur in patients anticoagulated with LMWH or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. These hematomas can result in long-term or permanent paralysis.
Increased risk of bleeding, especially in patients with renal impairment, uncontrolled hypertension, or history of gastrointestinal bleeding; thrombocytopenia (including heparin-induced thrombocytopenia); elevated serum potassium levels (hyperkalemia); use in pregnancy and lactation; elderly patients (increased bleeding risk).
Risk of bleeding, especially with invasive procedures or concomitant use of antiplatelet agents,Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS),Increased risk of spinal/epidural hematoma with neuraxial anesthesia,Use with caution in patients with renal impairment (creatinine clearance <30 m L/min) due to reduced clearance,Monitor for signs of bleeding and thrombocytopenia
Active major bleeding; history of heparin-induced thrombocytopenia (HIT); hypersensitivity to enoxaparin or heparin; patients undergoing regional anesthesia with known bleeding risk; severe uncontrolled hypertension; bacterial endocarditis; conditions with increased risk of hemorrhage (e.g., recent surgery, trauma, peptic ulcer disease, hemorrhagic stroke).
Active major bleeding,History of heparin-induced thrombocytopenia (HIT),Hypersensitivity to enoxaparin, heparin, or pork products,Use of indwelling epidural catheter for analgesia or therapy
No specific food interactions. Vitamin K-rich foods (leafy greens) do not significantly affect LMWH, in contrast to warfarin. Avoid excessive alcohol intake due to increased bleeding risk. Do not take supplements like fish oil, ginkgo, or ginger without consulting prescriber due to antiplatelet effects.
No specific food restrictions; avoid excessive alcohol consumption as it may increase bleeding risk.
Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second and third trimesters: no known risk, though there is a risk of maternal hemorrhage that could affect the fetus.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: No known increased risk of major malformations. Second/Third trimesters: Risk of maternal hemorrhage, placental abruption, and fetal hemorrhage due to anticoagulant effect. Use only if clearly needed.
Enoxaparin is not detected in breast milk due to its high molecular weight and protein binding; therefore, it is considered compatible with breastfeeding. M/P ratio: not applicable (not measurable).
Excreted in human milk in negligible amounts; M/P ratio not established. Considered compatible with breastfeeding; monitor infant for signs of bruising or bleeding.
Pregnancy increases clearance of enoxaparin; dose adjustments may be needed based on anti-Xa monitoring. Generally, dose adjustments are not routinely required for standard prophylactic doses, but therapeutic doses may need to be increased (e.g., weight-based dosing) and monitored. Avoid use in patients with active major bleeding or known hypersensitivity.
Renal blood flow increases during pregnancy, potentially increasing clearance. Dose adjustments may be needed in the third trimester based on anti-Xa monitoring. Standard prophylactic dose: 40 mg SC once daily; therapeutic dose: 1 mg/kg SC q12h. Consider weight-based dosing and monitor anti-Xa levels (target 0.5-1.0 IU/m L for therapeutic, 0.2-0.5 IU/m L for prophylaxis).
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-factor Xa levels in patients with renal impairment (Cr Cl <30 m L/min) and in pregnant women. Protamine sulfate partially reverses anticoagulation (approximately 60% anti-factor Xa activity). Avoid intramuscular injections due to hematoma risk. Epidural/spinal anesthesia increases risk of spinal hematoma; remove catheter at least 12 hours after last dose (or 24 hours if therapeutic dosing). Adjust dose for moderate renal impairment (Cr Cl 30-50 m L/min) in treatment of VTE or unstable angina.
Enoxaparin is a low molecular weight heparin (LMWH) with predictable pharmacokinetics, eliminating the need for routine monitoring of anti-Xa activity in most patients. Dosing is based on weight and renal function; adjust for Cr Cl <30 m L/min (e.g., 30 mg once daily for VTE prophylaxis). Protamine sulfate partially reverses anticoagulant effect (60% neutralization). Avoid in patients with history of heparin-induced thrombocytopenia (HIT); check platelet counts every 2-3 days during therapy. Subcutaneous injection technique: administer in lateral abdominal wall, pinch skin, insert needle at 45-90° angle, do not rub site. Spinal/epidural hematoma risk with neuraxial anesthesia — remove indwelling catheter at least 12 hours after last prophylactic dose (24 hours for treatment doses).
Do not skip doses; take at the same time each day.,Rotate injection sites (left and right sides of abdomen) and do not rub the site after injection.,Watch for signs of bleeding: unusual bruising, blood in urine/stool, prolonged bleeding from cuts, or bleeding from gums.,Seek emergency care if you have signs of a spinal blood clot (back pain, numbness/weakness in legs, loss of bowel or bladder control).,Avoid aspirin, NSAIDs (ibuprofen, naproxen), and other blood thinners unless prescribed by your doctor.,Tell all healthcare providers including dentists that you are taking enoxaparin.,Do not drive or operate heavy machinery if you feel dizzy or weak from bleeding.,Store enoxaparin at room temperature; do not freeze.
Inject enoxaparin exactly as prescribed; do not skip doses.,Rotate injection sites (left/right side of abdomen) to reduce bruising.,Do not massage the injection site after administration.,Watch for signs of bleeding: unusual bruising, black/tarry stools, pink/red urine, coughing up blood, or severe headache.,Seek emergency care for sudden back pain, numbness, or leg weakness (possible spinal hematoma).,Tell all healthcare providers you are taking this blood thinner before procedures or surgeries.,Use soft toothbrush and electric razor to minimize bleeding risk.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Enoxaparin vs LOVENOX, answered by our medical review team.
Enoxaparin is a Low Molecular Weight Heparin that works by Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.. LOVENOX is a Low Molecular Weight Heparin that works by Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Enoxaparin and LOVENOX depend on the specific clinical indication. These are both Low Molecular Weight Heparin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Enoxaparin is: 1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.. The standard adult dose of LOVENOX is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Enoxaparin and LOVENOX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Enoxaparin is classified as Category A/B. Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second a. LOVENOX is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: No known increased risk of major malformations. Second/Third trimesters: Risk of materna. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.